Analysts Unconvinced By Sanofi Best-In-Class Claims For Sarclisa
Much Ground To Make Up On J&J's Darzalex
Sanofi presented new data at a post-ASCO briefing to back its claim that Sarclisa can become the anti-CD38 of choice for the treatment of multiple myeloma ahead of Darzalex. The investment community is not so sure.
You may also be interested in...
The European Commission’s approval of GlaxoSmithKline’s Blenrep is one of the first major fruits of a refocused pipeline and development strategy at the big pharma company.
NICE is not yet convinced that Sanofi’s recently approved combination treatment for relapsed or refractory multiple myeloma is value for money. Temporary funding under the Cancer Drugs Fund has also been ruled out.
The gap between potential approvals for Bristol’s ide-cel and Janssen’s JNJ-4528 has narrowed as both CAR-T therapies show high response rates in multiple myeloma – and as bispecific antibodies, including Janssen’s teclistamab, edge into the space.